At the news
? NEUTRALIMPACT 3/10 8-K filed May 19, 2026 at 08:07 ET
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22, 2026 with a $135,000 severance; CEO Fred Aslan assumes the principal financial officer role; and Diego Miralles transitions from the Board to President and Head of R&D with a $600,000 salary and inducement equity grants of 232,500 options and 77,500 RSUs. The CFO departure without a named successor creates a temporary gap in financial leadership, though the CEO taking over the role suggests internal continuity.
- CFO Thad Huston agreed to separation effective May 22, 2026; no replacement named yet; receives ~$135,000 severance (3 months salary) plus COBRA.
- CEO Fred Aslan appointed as principal financial and accounting officer, adding to his CEO and board member roles.
- Diego Miralles resigned from the Board effective May 18, 2026 to become President and Head of R&D; receives $600,000 base salary, 45% target bonus, and inducement awards of 232,500 options + 77,500 RSUs.
- Board size reduced from 8 to 7 members following Miralles' departure.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access